The U.S. funding arrives from PEPFAR and goes to the Americas; $12.2 million is being directed to HIV services in Panama.

Drugmaker Gilead Sciences led in private HIV/AIDS funding, reports FCAA, noting “a dangerous reliance on a shrinking pool of funders.”